Metsera, Inc. Share Price

MTSR

US59267L1070

Biotechnology & Medical Research

Last Transcript: Metsera, Inc.

Metsera, Inc., Pfizer Inc. - M&A Call

22/09/25

More transcripts

Analysts' recommendations: Metsera, Inc.

11-10	Sector Update: Health Care Stocks Advance Late Afternoon	MT
11-10	Pfizer CEO Albert Bourla says Think Co will pay entire CVR for Metsera - CNBC interview	RE
11-10	Pfizer to Acquire Metsera Under Amended Deal; Novo Nordisk Says No Plan to Increase Offer for Metsera	MT
11-10	Pfizer wins tug-of-war over Metsera after raising its bid	FW
11-08	Metsera says Pfizer to buy Metsera for up to $86.25 per share	RE

More recommendations

News in other languages: Metsera, Inc.

11-26	Novo Nordisk rebondit après une demande d'approbation aux Etats-Unis
11-25	Novo Nordisk: Kein ruhiges Fahrwasser
11-25	Novo Nordisk: non va tutto liscio
11-25	Novo Nordisk: En vías de recuperación
11-25	Novo Nordisk: geen rustig vaarwater

More news

Metsera Inc is a United States-based biopharmaceutical company. The Company is engaged in developing medicines and solutions for obesity and metabolic diseases. It offers a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with profiles to address multiple therapeutic targets and meet the future needs of a weight loss treatment landscape. Its solutions helps to reduce the physical, emotional, and economic burdens of obesity as a driver of diseases. In addition it offers HALO, which is a peptide lipidation platform technology, which enables peptides to bind simultaneously to albumin and to a drug target.

Employees

129

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

12-12	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-08	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
11-25	Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial -- Update	DJ
11-25	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
11-25	No plane sailing for Novo Nordisk
11-24	Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer's Trials -- Update	DJ
11-20	Major deals involving U.S. drugmakers and biotechs over the past decade	RE
11-18	Sector Update: Health Care Stocks Higher Tuesday Afternoon	MT
11-18	Pfizer Seeks to Raise $5 Billion in Bond Sale for Metsera Deal	MT
11-18	Pfizer Seeking at Least $5 Billion in Bond Sale for Metsera Deal	MT
11-18	Pfizer Seeking at Least $5 Billion in Bond Sale for Metsera Deal, Bloomberg Reports	MT
11-17	Metsera, Inc.(NasdaqGS:MTSR) dropped from S&P Global BMI Index	CI
11-17	Metsera, Inc.(NasdaqGS:MTSR) dropped from S&P Biotechnology Select Industry Index	CI

11-10	Novo Nordisk will not increase its proposal to acquire Metsera, Inc.	AQ
11-08	Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk	AQ
11-08	Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer	PR
11-06	Metsera Issues Statement in Response to Litigation Ruling	PR
11-04	Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
METSERA, INC.	-0.35%	-15.24%	-	-	7.43B
ARGENX SE	+0.29%	+0.57%	+12.81%	+97.19%	50.26B
WUXI APPTEC CO., LTD.	0.00%	-5.76%	+78.85%	+0.10%	41.75B
INSMED INCORPORATED	-2.61%	-1.92%	+99.12%	+648.13%	34.21B
BIONTECH SE	-2.10%	+9.34%	+0.70%	-18.78%	29.73B
WUXI BIOLOGICS (CAYMAN) INC.	+0.92%	-1.75%	+122.90%	-44.89%	20.65B
GENMAB A/S	+0.57%	-1.57%	+41.06%	-22.26%	20.51B
AKESO, INC.	+3.65%	-4.43%	+86.10%	+143.72%	13.28B
SUMMIT THERAPEUTICS INC.	-5.07%	-4.52%	-29.89%	+275.63%	13.39B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.07%	-8.67%	+169.00%	-	12.46B
Average	-0.16%	-1.71%	+64.52%	+134.86%	26.25B
Weighted average by Cap.	-0.37%	-0.62%	+57.47%	+137.27%

Metsera, Inc. Share Price

Equities

MTSR

US59267L1070

Biotechnology & Medical Research

Chart: Metsera, Inc.

Latest news: Metsera, Inc.

Last Transcript: Metsera, Inc.

Analysts' recommendations: Metsera, Inc.

Press Releases: Metsera, Inc.

News in other languages: Metsera, Inc.

Quotes and Performance

Bio Therapeutic Drugs

Company Profile